CYP27B1 Antibody (C-term)
Purified Mouse Monoclonal Antibody (Mab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | O15528 |
Reactivity | Human |
Predicted | Human |
Host | Mouse |
Clonality | monoclonal |
Isotype | IgG1,κ |
Clone/Animal Names | 1981CT820.303.81 |
Calculated MW | 56504 Da |
Gene ID | 1594 |
---|---|
Other Names | 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, 1.14.13.13, 25-OHD-1 alpha-hydroxylase, 25-hydroxyvitamin D(3) 1-alpha-hydroxylase, VD3 1A hydroxylase, Calcidiol 1-monooxygenase, Cytochrome P450 subfamily XXVIIB polypeptide 1, Cytochrome P450C1 alpha, Cytochrome P450VD1-alpha, Cytochrome p450 27B1, CYP27B1, CYP1ALPHA, CYP27B |
Target/Specificity | This CYP27B1 antibody is generated from a mouse immunized with a KLH conjugated synthetic peptide between 477-508 amino acids from the C-terminal region of human CYP27B1. |
Dilution | WB~~1:1000 |
Format | Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | CYP27B1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | CYP27B1 |
---|---|
Synonyms | CYP1ALPHA, CYP27B |
Function | A cytochrome P450 monooxygenase involved in vitamin D metabolism and in calcium and phosphorus homeostasis. Catalyzes the rate-limiting step in the activation of vitamin D in the kidney, namely the hydroxylation of 25-hydroxyvitamin D3/calcidiol at the C1alpha- position to form the hormonally active form of vitamin D3, 1alpha,25- dihydroxyvitamin D3/calcitriol that acts via the vitamin D receptor (VDR) (PubMed:10518789, PubMed:10566658, PubMed:12050193, PubMed:22862690, PubMed:9486994). Has 1alpha-hydroxylase activity on vitamin D intermediates of the CYP24A1-mediated inactivation pathway (PubMed:10518789, PubMed:22862690). Converts 24R,25-dihydroxyvitamin D3/secalciferol to 1-alpha,24,25-trihydroxyvitamin D3, an active ligand of VDR. Also active on 25-hydroxyvitamin D2 (PubMed:10518789). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via FDXR/adrenodoxin reductase and FDX1/adrenodoxin (PubMed:22862690). |
Cellular Location | Mitochondrion membrane. |
Tissue Location | Kidney. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Catalyzes the conversion of 25-hydroxyvitamin D3 (25(OH)D) to 1-alpha,25-dihydroxyvitamin D3 (1,25(OH)2D) plays an important role in normal bone growth, calcium metabolism, and tissue differentiation.
References
Fu G.K.,et al.DNA Cell Biol. 16:1499-1507(1997).
Monkawa T.,et al.Biochem. Biophys. Res. Commun. 239:527-533(1997).
Fu G.K.,et al.Mol. Endocrinol. 11:1961-1970(1997).
Huang D.C.,et al.Mol. Cancer Res. 1:56-67(2002).
Huang D.C.,et al.Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.